Annexon Biosciences

10 articles with Annexon Biosciences

•  Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma

  10/9/2019

  Intravitreal ANX007 was well-tolerated and demonstrated full target engagement and inhibition of C1q in the eye for at least four weeks

• Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome

  9/30/2019

  Annexon Biosciences announced encouraging results from a Phase 1b dose-ranging clinical trial to evaluate its anti-C1q antibody, ANX005.

• Annexon Biosciences Announces FDA Fast Track Designation for Novel C1q Inhibitor ANX005 for the Treatment of Guillain-Barré Syndrome

  9/23/2019

  Annexon plans to advance the clinical development of ANX005 for the treatment of GBS

• 

  BioSpace Movers and Shakers, July 12

  7/12/2019

  Biotech and pharma companies strengthen their leadership teams with new appointments.

• Annexon Biosciences Expands Senior Leadership as it Advances its Novel Complement Approach to Autoimmune and Neurodegenerative Disorders

  7/9/2019

  Sanjay Keswani, MBBS, BSc, FRCP, Chief Medical Officer Jennifer Lew, Chief Financial Officer Lesley Stolz, PhD, Chief Business Officer

• 

  Companies Note Collaborations, Financing and Clinical Trial Success

  12/26/2018

  With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.

• Annexon Biosciences Closes $75 Million Financing

  12/19/2018

  Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing.

• Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor

  6/12/2018

  BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.

• Annexon Appoints Bill Young As Chairman And Adds Tom Wiggans To Board Of Directors

  3/9/2017

• Bay Area Startup Annexon Banks $44 Million Series B

  6/23/2016